Search filters
Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 372
  • 1194
  • 567
  • 28
  • 43
  • 2
  • 1127
  • 1195
  • 5

Found 1200 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

18 years - 99 years
All genders
Phase 2
The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an inactive substance) in patients with Non-obstructive Hypertrophic Cardiomyopathy (nHCM).
Learn More
A RANDOMIZED DOUBLE BLINDED CONTROLLED TRIAL OF A RAPID PLEURODESIS PROTOCOL AFTER INDWELLING PLEURAL CATHETER PLACEMENT FOR MALIGNANT PLEURAL EFFUSIONS (THE RAPID TRIAL)

A RANDOMIZED DOUBLE BLINDED CONTROLLED TRIAL OF A RAPID PLEURODESIS PROTOCOL AFTER INDWELLING PLEURAL CATHETER PLACEMENT FOR MALIGNANT PLEURAL EFFUSIONS (THE RAPID TRIAL)

99 years or below
All genders
Please see attached protocol, pages 7-9
Learn More
An extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension

An extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension

99 years or below
All genders
Phase 3
This is a Phase 3a, extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension. The purpose of this study is to provide or continue to provide bardoxolone methyl to eligible subjects who participated in the CATALYST study. The study will also collect ongoing safety …
Learn More
UPCC 11417: A Phase 3 Multicenter Randomized Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

UPCC 11417: A Phase 3 Multicenter Randomized Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

99 years or below
All genders
Phase 3
Request for collaborative review: WIRB serving as IRB of record.
Learn More
UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma

UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma

99 years or below
All genders
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
Learn More
Zoster Eye Disease Study (ZEDS): A multi-center randomized double-masked placebo-controlled study of valacyclovir in immunocompetent subjects with a history of dendriform epithelial keratitis stromal keratitis endothelial keratitis and/or iritis due to Herpes Zoster Ophthalmicus (HZO) within the year prior to enrollment.

Zoster Eye Disease Study (ZEDS): A multi-center randomized double-masked placebo-controlled study of valacyclovir in immunocompetent subjects with a history of dendriform epithelial keratitis stromal keratitis endothelial keratitis and/or iritis due to Herpes Zoster Ophthalmicus (HZO) within the year prior to enrollment.

99 years or below
All genders
Phase 3
Request to rely on the lead site IRB, see attached documents
Learn More
UPCC 25417: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

UPCC 25417: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

99 years or below
All genders
Phase 3
Request for collaborative review: Sterling IRB serving as IRB of record.
Learn More
UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

99 years or below
All genders
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
Learn More
Prospective Randomized Double-Blinded Controlled Multi-Center Clinical Trial Evaluating the Use of Non-Invasive CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

Prospective Randomized Double-Blinded Controlled Multi-Center Clinical Trial Evaluating the Use of Non-Invasive CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

99 years or below
All genders
TBD
Learn More
A Multiple-Site Phase 1/2 Safety and Efficacy Trial of AGTC 402 a Recombinant Adeno-associated Virus Vector Expressing CNGA3 in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

A Multiple-Site Phase 1/2 Safety and Efficacy Trial of AGTC 402 a Recombinant Adeno-associated Virus Vector Expressing CNGA3 in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

99 years or below
All genders
Phase 2
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 25% are caused …
Learn More
181 - 190 of 1200